Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

The gloom deepens for biopharma stocks
EP Vantage
Mon, 10/10/22 - 06:54 pm
Tags:
biopharma stocks, AbbVie, Alnylam, AstraZeneca, Biogen, CRISPR Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, GSK, Intellia Therapeutics, Regeneron, Roche, Sanofi, Sarepta Therapeutics
BioSpace Layoff Tracker 2022: Cyclerion, OncoSec Implement Restructuring Initiatives
BioSpace
Fri, 10/7/22 - 10:45 am
Tags:
layoffs, Cyclerion, OncoSec, Exicure, AbbVie, Bristol Myers Squibb, Palisade Bio, ObsEva, Rubius Therapeutics, Novartis, Finch Therapeutics
Q3 2022: Layoffs Continue, Alzheimer’s Soars and Accelerated Approvals Fall
BioSpace
Mon, 10/3/22 - 11:33 pm
Tags:
layoffs, Vesalius Therapeutics, AbbVie, Bristol Myers Squibb, Palisade Bio, IBV, Zymergen
Where Will AbbVie Be in 3 Years?
Motley Fool
Fri, 09/30/22 - 10:50 am
Tags:
AbbVie, Humira, biosimilars, Rinvoq, Skyrizi, Vraylar
As lead drug flopped and AbbVie collab dissolved, cancer biotech resorts to buying rare disease company
Endpoints
Thu, 09/29/22 - 10:02 am
Tags:
Idera Pharmaceuticals, AbbVie, Aceragen, M&A
AbbVie and BMS slash 360 jobs in California, the latest in a streak of biopharma layoffs
Fierce Pharma
Sun, 09/18/22 - 10:45 pm
Tags:
AbbVie, Bristol Myers Squibb, layoffs, California
AbbVie unveils 'See Yourself' Botox campaign, days after new rival approved
Endpoints
Tue, 09/13/22 - 08:06 pm
Tags:
AbbVie, Allergan, Botox, DTC ads, Daxxify, Revance Therapeutics
Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's Humira?
Fierce Pharma
Tue, 09/13/22 - 08:03 pm
Tags:
Novartis, FDA, Cosentyx, AbbVie, Humira, hidradenitis suppurativa
Longer-lasting Botox competitor nabs FDA approval — can it compete with AbbVie's $2B cash cow?
Endpoints
Thu, 09/8/22 - 11:04 am
Tags:
Revance Therapeutics, FDA, Daxxify, aesthetics, AbbVie, Botox
FDA holds back Alvotech’s Humira biosimilar over manufacturing issues
BioPharma Dive
Tue, 09/6/22 - 04:57 pm
Tags:
Alvotech, AbbVie, Humira, biosimilars, FDA, drug manufacturing
Kymera’s pain could be Priovant’s gain
EP Vantage
Tue, 08/30/22 - 11:41 am
Tags:
Pfizer, hidradenitis suppurativa, Kymera, Priovant, AbbVie
AbbVie fends off patent claim in unusual whistleblower case
Fierce Pharma
Fri, 08/26/22 - 12:18 pm
Tags:
AbbVie, whistleblower lawsuits, whistleblowers, Allergan, Adamas, Alzheimer's disease
AbbVie, J&J's Imbruvica wins first pediatric nod, this one for chronic graft-versus-host disease
Fierce Pharma
Thu, 08/25/22 - 11:04 am
Tags:
JNJ, AbbVie, Imbruvica, graft vs host disease, pediatric, FDA
AbbVie calls off PhI trial for I-Mab’s CD47 days after Zai Lab shelves its own program
Endpoints
Tue, 08/16/22 - 11:59 pm
Tags:
AbbVie, CD47, SEC, clinical trials, I-Mab, Zai Lab
Pursuing AbbVie and J&J, Innovent hits primary endpoint in phase 2 psoriasis trial
Fierce Biotech
Wed, 08/10/22 - 10:49 am
Tags:
Innovent, AbbVie, JNJ, monoclonal antibodies, psoriasis, clinical trials
'What’s wrong with having lots of patents?' Federal appeals judge sides with AbbVie in Humira case
Endpoints
Tue, 08/2/22 - 11:22 pm
Tags:
AbbVie, Humira, patents
AbbVie gives Sosei a StaRring role in neurological drug discovery plans, paying $40M and committing $1.2B
Fierce Biotech
Tue, 08/2/22 - 10:48 am
Tags:
AbbVie, Sosei Heptares, neurological disorders, drug discovery
Lilly, AZ, AbbVie and J&J face big potential hit from Medicare pricing bill: analysts
Fierce Pharma
Mon, 08/1/22 - 10:53 am
Tags:
Eli Lilly, AstraZeneca, JNJ, AbbVie, legislation, drug pricing, Medicare
In last Q2 with Humira market lock, AbbVie leans on best-seller to offset Imbruvica losses
Fierce Pharma
Mon, 08/1/22 - 10:35 am
Tags:
AbbVie, earnings, Humira
FDA reviewing higher dose Hyrimoz biosimilar
Biopharma Reporter
Fri, 07/22/22 - 11:14 am
Tags:
FDA, Sandoz, biosimilars, Hyrimoz, Humira, AbbVie

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.